insights_auto
Outlook: 60.9% bullish·0.0% bearish
Go to analysischevron_right
TNDM:NASDAQ
Tandem Diabetes Care Inc
$17.05
arrow_downward
-0.06%(-0.010) 1D
$17.04
arrow_downward
-0.05% (-0.0085)bedtimeAfter hours
Closed: Nov 18, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNDM...
Open
$17.68
High
$18.29
Low
$16.79
Mkt. cap
1.19B
Avg. vol.
2.60M
Volume
2.00
52-wk high
$29.65
52-wk low
$12.26
EPS
-$0.72
Beta
1.59
Shares outstanding
69.79M
No. of employees
2K
Open
$17.68
High
$18.29
Low
$16.79
Mkt. cap
1.19B
Avg. vol.
2.60M
Volume
2.00
52-wk high
$29.65
52-wk low
$12.26
EPS
-$0.72
Beta
1.59
Shares outstanding
69.79M
No. of employees
2K
News stories
From web sources and news partners
Seeking Alpha
·
18 hours ago
Tandem upgraded, Insulet downgraded at Stifel on market for tubeless insulin pumps
Benzinga
·
19 hours ago
This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Yahoo Finance
·
22 hours ago
Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls
GuruFocus
·
23 hours ago
TNDM Upgraded by Stifel -- Price Target Raised to $26.00
Profile
Tandem Diabetes Care, Inc. is an American medical-device company that develops and markets insulin pumps, automated insulin delivery systems and diabetes-management software. Headquartered in San Diego, California, its principal pump platforms are the t:slim X2 and Tandem Mobi, both of which use the company's Control-IQ+ software with compatible continuous glucose monitors.
Tandem was founded in 2006 and introduced its first pump, the touchscreen t:slim, in 2012. The company became publicly traded on the Nasdaq in 2013. By the end of 2025 it reported an in-warranty user base of nearly 500,000 people in more than 25 countries and annual sales of $1.015 billion. Wikipedia
About Tandem Diabetes Care Inc
CEOJohn Sheridan
Employees2.5K
FoundedJan 2006
Headquarters-
SectorHealth Care
IndustryMedical device
Websitetandemdiabetes.com